
Exagen XGN
$ 3.06
1.66%
Annual report 2025
added 03-10-2026
Exagen Book Value 2011-2026 | XGN
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Exagen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.4 M | 9.54 M | 22.7 M | 42.5 M | 84.9 M | 41.8 M | 55.7 M | -6.73 M | -4.64 M | - | -22.2 M | -14.1 M | 451 K | 4.82 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 84.9 M | -22.2 M | 17.9 M |
Quarterly Book Value Exagen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.1 M | 21 M | 6.4 M | 9.54 M | 12.9 M | 17.6 M | 20 M | 22.7 M | 27.5 M | 31.9 M | 35.9 M | 42.5 M | 56.2 M | 62.8 M | 76.2 M | 84.9 M | 90.8 M | 96.4 M | 101 M | 41.8 M | 41.8 M | 41.8 M | 41.8 M | 55.7 M | 55.7 M | 55.7 M | 55.7 M | -6.73 M | -6.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 101 M | -6.73 M | 41.8 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
5.39 B | $ 115.48 | 0.82 % | $ 35.1 B | ||
|
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 16.2 | -0.61 % | $ 175 M | ||
|
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | ||
|
Biodesix
BDSX
|
20.9 M | $ 15.07 | 2.1 % | $ 1.95 B | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Co-Diagnostics
CODX
|
20.6 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 24.84 | -0.84 % | $ 690 M | ||
|
BioNano Genomics
BNGO
|
44.4 M | $ 1.2 | 0.84 % | $ 6.53 M | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 173.89 | -0.58 % | $ 8.62 B | ||
|
DarioHealth Corp.
DRIO
|
110 M | $ 8.4 | 3.7 % | $ 33.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
2.75 B | $ 62.22 | -0.24 % | $ 24.3 B | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.17 | -0.91 % | $ 4.98 M | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Celcuity
CELC
|
101 M | $ 112.63 | -0.27 % | $ 5.27 B | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 16.82 | 2.31 % | $ 509 M | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.02 | 0.17 % | $ 22 B | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Guardant Health
GH
|
-99.3 M | $ 93.83 | 2.94 % | $ 11.8 B | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 114.19 | 2.49 % | $ 9.42 B | ||
|
Interpace Biosciences
IDXG
|
22.4 M | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
IDEXX Laboratories
IDXX
|
1.61 B | $ 569.55 | 0.87 % | $ 45.8 B | ||
|
IQVIA Holdings
IQV
|
6.63 B | $ 173.26 | 0.5 % | $ 29.8 B | ||
|
Illumina
ILMN
|
6.3 B | $ 127.38 | 0.59 % | $ 20.3 B | ||
|
Koninklijke Philips N.V.
PHG
|
11 B | $ 27.11 | -0.66 % | $ 20 B | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 76.1 | 0.53 % | $ 5.14 B | ||
|
Medpace Holdings
MEDP
|
459 M | $ 498.34 | 1.81 % | $ 14.4 B | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 273.72 | 0.36 % | $ 22.8 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Sotera Health Company
SHC
|
606 M | $ 14.96 | 0.61 % | $ 4.25 B | ||
|
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 259.94 | -1.11 % | $ 26 B | ||
|
Myriad Genetics
MYGN
|
368 M | $ 4.75 | 3.49 % | $ 440 M | ||
|
NeoGenomics
NEO
|
837 M | $ 8.0 | 3.23 % | $ 1.02 B | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 9.41 | 0.21 % | $ 2.04 B | ||
|
CareDx, Inc
CDNA
|
303 M | $ 18.31 | 2.46 % | $ 976 M | ||
|
National Research Corporation
NRC
|
14 M | $ 17.16 | -1.04 % | $ 384 M |